Use of selective serotonin reuptake inhibitors and outcomes in pulmonary arterial hypertension

Ali Sadoughi, Kari E. Roberts, Ioana R. Preston, Ginny P. Lai, Deborah H. McCollister, Harrison W. Farber, Nicholas S. Hill

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background: Selective serotonin reuptake inhibitors (SSRIs) have been suggested to offer therapeutic benefi t in patients with pulmonary arterial hypertension (PAH). We conducted two analyses to explore the association between SSRI use and PAH outcomes using the Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL Registry). Methods: First, new users (SSRI-naive patients who initiated treatment after enrollment, incident use analysis, n = 220) were matched (1:2) with non-SSRI users (nonusers, n = 440) by enrollment center, sex, date of most recent visit, age, and 6-min walk distance. Second, a cross-sectional design was used to compare nonusers (n = 2,463), high-affi nity SSRI users (n = 430), and non-high-affi nity SSRI users (n = 125) at enrollment. Mortality and a composite end point defi ned by events indicative of clinical worsening were evaluated. Results: New users had a higher risk of death (unadjusted hazard ratio [HR], 1.74; 95% CI, 1.19-2.54; P = .004) and were less likely to be free from the composite end point 2 years after enrollment vs nonusers (25.7% vs 43.2%, respectively; P <.001). Similarly, among prevalent SSRI users (patients with a history of SSRI use at enrollment), high-affi nity SSRI users were less likely to be free from the composite end point vs nonusers (unadjusted HR, 1.20; 95% CI, 1.07-1.36; P = .003). In both analyses, differences in outcome were maintained after adjustment for clinical variables previously associated with PAH outcomes. Conclusions: In a large population of patients with PAH, incident SSRI use was associated with increased mortality and a greater risk of clinical worsening, although we could not adjust for all potential confounders.

Original languageEnglish (US)
Pages (from-to)531-541
Number of pages11
JournalChest
Volume144
Issue number2
DOIs
StatePublished - Aug 2013
Externally publishedYes

Fingerprint

Serotonin Uptake Inhibitors
Pulmonary Hypertension
Registries
Mortality
Disease Management

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Sadoughi, A., Roberts, K. E., Preston, I. R., Lai, G. P., McCollister, D. H., Farber, H. W., & Hill, N. S. (2013). Use of selective serotonin reuptake inhibitors and outcomes in pulmonary arterial hypertension. Chest, 144(2), 531-541. https://doi.org/10.1378/chest.12-2081

Use of selective serotonin reuptake inhibitors and outcomes in pulmonary arterial hypertension. / Sadoughi, Ali; Roberts, Kari E.; Preston, Ioana R.; Lai, Ginny P.; McCollister, Deborah H.; Farber, Harrison W.; Hill, Nicholas S.

In: Chest, Vol. 144, No. 2, 08.2013, p. 531-541.

Research output: Contribution to journalArticle

Sadoughi, A, Roberts, KE, Preston, IR, Lai, GP, McCollister, DH, Farber, HW & Hill, NS 2013, 'Use of selective serotonin reuptake inhibitors and outcomes in pulmonary arterial hypertension', Chest, vol. 144, no. 2, pp. 531-541. https://doi.org/10.1378/chest.12-2081
Sadoughi, Ali ; Roberts, Kari E. ; Preston, Ioana R. ; Lai, Ginny P. ; McCollister, Deborah H. ; Farber, Harrison W. ; Hill, Nicholas S. / Use of selective serotonin reuptake inhibitors and outcomes in pulmonary arterial hypertension. In: Chest. 2013 ; Vol. 144, No. 2. pp. 531-541.
@article{bb7f2c0061b149f3a599a827fbd3ac79,
title = "Use of selective serotonin reuptake inhibitors and outcomes in pulmonary arterial hypertension",
abstract = "Background: Selective serotonin reuptake inhibitors (SSRIs) have been suggested to offer therapeutic benefi t in patients with pulmonary arterial hypertension (PAH). We conducted two analyses to explore the association between SSRI use and PAH outcomes using the Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL Registry). Methods: First, new users (SSRI-naive patients who initiated treatment after enrollment, incident use analysis, n = 220) were matched (1:2) with non-SSRI users (nonusers, n = 440) by enrollment center, sex, date of most recent visit, age, and 6-min walk distance. Second, a cross-sectional design was used to compare nonusers (n = 2,463), high-affi nity SSRI users (n = 430), and non-high-affi nity SSRI users (n = 125) at enrollment. Mortality and a composite end point defi ned by events indicative of clinical worsening were evaluated. Results: New users had a higher risk of death (unadjusted hazard ratio [HR], 1.74; 95{\%} CI, 1.19-2.54; P = .004) and were less likely to be free from the composite end point 2 years after enrollment vs nonusers (25.7{\%} vs 43.2{\%}, respectively; P <.001). Similarly, among prevalent SSRI users (patients with a history of SSRI use at enrollment), high-affi nity SSRI users were less likely to be free from the composite end point vs nonusers (unadjusted HR, 1.20; 95{\%} CI, 1.07-1.36; P = .003). In both analyses, differences in outcome were maintained after adjustment for clinical variables previously associated with PAH outcomes. Conclusions: In a large population of patients with PAH, incident SSRI use was associated with increased mortality and a greater risk of clinical worsening, although we could not adjust for all potential confounders.",
author = "Ali Sadoughi and Roberts, {Kari E.} and Preston, {Ioana R.} and Lai, {Ginny P.} and McCollister, {Deborah H.} and Farber, {Harrison W.} and Hill, {Nicholas S.}",
year = "2013",
month = "8",
doi = "10.1378/chest.12-2081",
language = "English (US)",
volume = "144",
pages = "531--541",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "2",

}

TY - JOUR

T1 - Use of selective serotonin reuptake inhibitors and outcomes in pulmonary arterial hypertension

AU - Sadoughi, Ali

AU - Roberts, Kari E.

AU - Preston, Ioana R.

AU - Lai, Ginny P.

AU - McCollister, Deborah H.

AU - Farber, Harrison W.

AU - Hill, Nicholas S.

PY - 2013/8

Y1 - 2013/8

N2 - Background: Selective serotonin reuptake inhibitors (SSRIs) have been suggested to offer therapeutic benefi t in patients with pulmonary arterial hypertension (PAH). We conducted two analyses to explore the association between SSRI use and PAH outcomes using the Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL Registry). Methods: First, new users (SSRI-naive patients who initiated treatment after enrollment, incident use analysis, n = 220) were matched (1:2) with non-SSRI users (nonusers, n = 440) by enrollment center, sex, date of most recent visit, age, and 6-min walk distance. Second, a cross-sectional design was used to compare nonusers (n = 2,463), high-affi nity SSRI users (n = 430), and non-high-affi nity SSRI users (n = 125) at enrollment. Mortality and a composite end point defi ned by events indicative of clinical worsening were evaluated. Results: New users had a higher risk of death (unadjusted hazard ratio [HR], 1.74; 95% CI, 1.19-2.54; P = .004) and were less likely to be free from the composite end point 2 years after enrollment vs nonusers (25.7% vs 43.2%, respectively; P <.001). Similarly, among prevalent SSRI users (patients with a history of SSRI use at enrollment), high-affi nity SSRI users were less likely to be free from the composite end point vs nonusers (unadjusted HR, 1.20; 95% CI, 1.07-1.36; P = .003). In both analyses, differences in outcome were maintained after adjustment for clinical variables previously associated with PAH outcomes. Conclusions: In a large population of patients with PAH, incident SSRI use was associated with increased mortality and a greater risk of clinical worsening, although we could not adjust for all potential confounders.

AB - Background: Selective serotonin reuptake inhibitors (SSRIs) have been suggested to offer therapeutic benefi t in patients with pulmonary arterial hypertension (PAH). We conducted two analyses to explore the association between SSRI use and PAH outcomes using the Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL Registry). Methods: First, new users (SSRI-naive patients who initiated treatment after enrollment, incident use analysis, n = 220) were matched (1:2) with non-SSRI users (nonusers, n = 440) by enrollment center, sex, date of most recent visit, age, and 6-min walk distance. Second, a cross-sectional design was used to compare nonusers (n = 2,463), high-affi nity SSRI users (n = 430), and non-high-affi nity SSRI users (n = 125) at enrollment. Mortality and a composite end point defi ned by events indicative of clinical worsening were evaluated. Results: New users had a higher risk of death (unadjusted hazard ratio [HR], 1.74; 95% CI, 1.19-2.54; P = .004) and were less likely to be free from the composite end point 2 years after enrollment vs nonusers (25.7% vs 43.2%, respectively; P <.001). Similarly, among prevalent SSRI users (patients with a history of SSRI use at enrollment), high-affi nity SSRI users were less likely to be free from the composite end point vs nonusers (unadjusted HR, 1.20; 95% CI, 1.07-1.36; P = .003). In both analyses, differences in outcome were maintained after adjustment for clinical variables previously associated with PAH outcomes. Conclusions: In a large population of patients with PAH, incident SSRI use was associated with increased mortality and a greater risk of clinical worsening, although we could not adjust for all potential confounders.

UR - http://www.scopus.com/inward/record.url?scp=84881535681&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881535681&partnerID=8YFLogxK

U2 - 10.1378/chest.12-2081

DO - 10.1378/chest.12-2081

M3 - Article

VL - 144

SP - 531

EP - 541

JO - Chest

JF - Chest

SN - 0012-3692

IS - 2

ER -